These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 9350694)

  • 1. Are biocompatible membranes superior for hemodialysis therapy?
    van Ypersele de Strihou C
    Kidney Int Suppl; 1997 Nov; 62():S101-4. PubMed ID: 9350694
    [No Abstract]   [Full Text] [Related]  

  • 2. Beta 2-microglobulin associated amyloidosis and therapy with high flux hemodialysis membranes.
    Floege J; Koch KM
    Clin Nephrol; 1994 Jul; 42 Suppl 1():S52-6. PubMed ID: 7923985
    [No Abstract]   [Full Text] [Related]  

  • 3. Myeloperoxidase serves as a marker of oxidative stress during single haemodialysis session using two different biocompatible dialysis membranes.
    Krieter DH; Lemke HD; Wanner C
    Nephrol Dial Transplant; 2006 Feb; 21(2):546; author reply 546. PubMed ID: 16249195
    [No Abstract]   [Full Text] [Related]  

  • 4. The pathogenesis and consequences of AGE formation in uraemia and its treatment.
    Dawnay A; Millar DJ
    Cell Mol Biol (Noisy-le-grand); 1998 Nov; 44(7):1081-94. PubMed ID: 9846890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemodialysis using high flux membranes improves lipid profiles.
    Blankestijn PJ
    Clin Nephrol; 1994 Jul; 42 Suppl 1():S48-51. PubMed ID: 7923984
    [No Abstract]   [Full Text] [Related]  

  • 6. Dialysis membrane biocompatibility: effects on cellular elements.
    Coli L; De Sanctis LB; Feliciangeli G; Iannelli S; Scolari MP; Todeschini P; Tumietto F; Costigliola P; Chiodo F
    Nephrol Dial Transplant; 1995; 10 Suppl 10():27-32. PubMed ID: 8825429
    [No Abstract]   [Full Text] [Related]  

  • 7. [Changes in the picture of chronic diseases on long-term hemodialysis treatment].
    von Appen K; Ivanovich P; Klinkmann H; Stetsiuk E
    Urol Nefrol (Mosk); 1995; (5):25-7. PubMed ID: 8571479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxidative stress parameters in hemodialysis patients with or without diabetes.
    Atanasiu V; Stoian I; Căpuşă C; Mircescu G; Mărăcine M; Lupescu O; Vîrgolici B; Muscurel C; Manolescu B
    Rom J Intern Med; 2006; 44(4):433-42. PubMed ID: 18386620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beta-2-microglobulin removal by hemodialysis with polymethylmethacrylate membranes.
    Campistol JM; Torregrosa JV; Ponz E; Fenollosa B
    Contrib Nephrol; 1999; 125():76-85. PubMed ID: 9895432
    [No Abstract]   [Full Text] [Related]  

  • 10. Atherosclerosis in patients undergoing maintenance hemodialysis.
    Bagdade JD
    Kidney Int Suppl; 1975 Feb; (3):370-2. PubMed ID: 169427
    [No Abstract]   [Full Text] [Related]  

  • 11. [Countermeasure for patients with amyloidosis due to hemodialysis].
    Gejo F
    Nihon Naika Gakkai Zasshi; 1995 Oct; 84(10):1673-7. PubMed ID: 8537723
    [No Abstract]   [Full Text] [Related]  

  • 12. Oxidative stress and uremia.
    Floccari F; Aloisi C; Crascì E; Sofi T; Campo S; Tripodo D; Criseo M; Frisina N; Buemi M
    Med Res Rev; 2005 Jul; 25(4):473-86. PubMed ID: 15660443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-efficiency dialysis with PMMA dialyzers: treatment dose delivery and long-term results.
    David S; Cambi V
    Contrib Nephrol; 1999; 125():96-110. PubMed ID: 9895434
    [No Abstract]   [Full Text] [Related]  

  • 14. Reactive carbonyl compounds related uremic toxicity ("carbonyl stress").
    Miyata T; Sugiyama S; Saito A; Kurokawa K
    Kidney Int Suppl; 2001 Feb; 78():S25-31. PubMed ID: 11168978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Biocompatibility].
    Uematsu K; Akizawa T
    Nihon Rinsho; 2004 May; 62 Suppl 5():37-40. PubMed ID: 15197884
    [No Abstract]   [Full Text] [Related]  

  • 16. Oxidatively-modified and glycated proteins as candidate pro-inflammatory toxins in uremia and dialysis patients.
    Piroddi M; Depunzio I; Calabrese V; Mancuso C; Aisa CM; Binaglia L; Minelli A; Butterfield AD; Galli F
    Amino Acids; 2007; 32(4):573-92. PubMed ID: 17356806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased risk of malignancy and blood-membrane interactions in uraemic patients.
    Akizawa T; Kinugasa E; Koshikawa S
    Nephrol Dial Transplant; 1994; 9 Suppl 2():162-4. PubMed ID: 8065609
    [No Abstract]   [Full Text] [Related]  

  • 18. Increased soluble CD14 levels in patients on hemodialysis. Influence of dialysate endotoxin or incompatibility to dialyzer membranes?
    Mitzner S; Stange J; Pichel K; Handschuk I; Korten G; Ehlers M; Schutt C; Schmidt R
    ASAIO J; 1995; 41(3):M707-8. PubMed ID: 8573897
    [No Abstract]   [Full Text] [Related]  

  • 19. Amyloidosis in patients with end-stage renal failure: uraemia associated or dialysis related?
    Davison AM
    Contrib Nephrol; 1995; 113():92-100. PubMed ID: 7712726
    [No Abstract]   [Full Text] [Related]  

  • 20. Oxidative stress: an accomplice to uremic toxicity?
    Mircescu G
    J Ren Nutr; 2006 Jul; 16(3):194-8. PubMed ID: 16825018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.